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OBJECTIVE: To assess the efficacy and safety of sitagliptin compared with voglibose added to combined
metformin and insulin in patients with newly diagnosed type 2 diabetes (T2DM).
METHODS: In this 12-week prospective, randomized, parallel trial, 70 newly diagnosed T2DM patients with
glycosylated hemoglobin (HbA1c) X9% and/or fasting plasma glucose (FPG) X11.1 mmol/L were randomized
(1:1) to receive sitagliptin 100 mg per day + metformin + insulin glargine or voglibose 0.2 mg three times
daily + metformin + insulin glargine. Change in HbA1c at week 12 was the primary endpoint.
RESULTS: The mean baseline HbA1c was 11.0% in the patients. The changes in HbA1c from baseline were -6.00%
in the sitagliptin group and -3.58% in the voglibose group, and the between-group difference was -2.42% (95%
CI -1.91 to -2.93, p=0.02). The differences in FPG and homeostatic model assessment of b-cell function (HOMA-b)
and the change in body weight between groups from baseline were -2.95 mmol/L (p=0.04), 43.91 (p=0.01) and
-2.23 kg (p=0.01), respectively. One patient (2.9%) in the sitagliptin group and three patients (8.6%) in the
voglibose group exhibited hypoglycemia.
CONCLUSIONS: Sitagliptin added to combined metformin and insulin therapy showed greater efficacy and
good safety regarding hypoglycemia in patients with newly diagnosed T2DM compared with voglibose.
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’ INTRODUCTION
The prevalence of diabetes in China is as high as 11.6% (1).
The main cause of disability and death are complications of
diabetes. Approximately 10% of the national health budget
is expended on treating diabetes and its complications (2).
Good blood glucose control is an important measure that can
delay the development of diabetic complications.
For newly diagnosed type 2 diabetes (T2DM) patients,
choosing an appropriate hypoglycemic treatment strategy is
crucial to achieve the goal of lowering blood glucose levels
stably and safely. For patients with glycosylated hemoglobin
(HbA1c) greater than 9% or fasting plasma glucose (FPG)
greater than 11.1 mmol/L, insulin should be chosen to
reduce blood glucose levels quickly (2) and relieve the
effect of hyperglycemia on apoptosis, dedifferentiation
and transdifferentiation of islet beta cells, and recovery
islet cell function (3). Metformin, the only first-line and
antihyperglycemic therapy drug for T2DM, appears in
many diabetes treatment guidelines around the world (2,4).
Metformin can reduce hepatic glucose output, promote
glucose uptake and utilization in peripheral tissue, and
improve insulin resistance. Metformin combined with
insulin targets two pathogenic aspects, insulin resistance
and secretion defects in T2DM.
Voglibose primarily inhibits invertase and maltase and
ultimately inhibits the degradation of disaccharides into
monosaccharides (5). Voglibose monotherapy can decrease
HbA1c levels by 0.5%B1.4% (6). Dipeptidyl peptidase-4
(DPP-4) inhibitors delay the degradation of glucagon-like
peptide-1 (GLP-1) and increase endogenous GLP-1 levels,
thus promoting insulin secretion (7). For patients with
a mean initial HbA1c of 7.8%, sitagliptin monotherapy
decreased HbA1c by 0.7% compared with placebo in
treatment-naive T2DM patients (8). Studies have shown that
for T2DM patients with poor blood glucose control, sitagliptin
monotherapy (9) or sitagliptin added to metformin (10) have a
significantly stronger effect of reducing HbA1c levels than
voglibose monotherapy or voglibose and metformin com-
bined. For T2DM patients who already receive insulin
treatment, addition of sitagliptin can lead to a significantly
higher decrease in HbA1c than addition of voglibose (11,12).
Our previous studies used continuous subcutaneous insulin
injection combined with either sitagliptin or voglibose to treatDOI: 10.6061/clinics/2019/e736
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newly diagnosed T2DM and confirmed that after two weeks
of treatment, sitagliptin had a stronger effect on decreasing mean
blood glucose, fasting blood glucose and glucose fluctuation (13).
At present, no studies have been carried out on the long-
term efficacy of adding sitagliptin compared with vogli-
bose to combined metformin and insulin therapy for the
treatment of newly diagnosed T2DM patients experienc-
ing high glucose toxicity. In the present study, we added
sitagliptin or voglibose to combined metformin and insulin
therapy for treating newly diagnosed T2DM patients with
HbA1cX9.0% and/or FPGX11.1 mmol/L. Twelve weeks
later, the efficacy and safety of these two treatments were
compared and analyzed.
’ MATERIALS AND METHODS
Design and subjects
This study used a randomized, prospective, parallel
design. A total of 83 newly diagnosed T2DM patients from
the First Affiliated Hospital of Dalian Medical University
were screened. Patients were diagnosed with T2DM within
the past year according to the 2013 American Diabetes
Association (ADA) criteria, age from 18 to 65 years and fasting
FPGX11.1 mmol/L and/or HbA1cX9%. These patients had
never taken oral hypoglycemic agents or received insulin
treatment prior to their participation in the present trial.
The exclusion criteria were as follows: the presence of
acute complications of diabetes, such as diabetic ketoacidosis
or hyperosmolar hyperglycemic syndrome; severe cardio-
vascular or cerebrovascular events within the past 6 months;
kidney damage (estimated glomerular filtration rate less than
60 ml/min  1.73 m2), or liver damage (alanine aminotrans-
ferase or aspartate aminotransferase 2.5 times more than the
normal upper limit); the presence of a tumor, severe infec-
tion, or stress; a history of acute pancreatitis; or a history of
gastrointestinal surgery.
The protocol was approved by the ethics committee of the
First Affiliated Hospital of Dalian Medical University (Ethics
References No: YJ-KY-FB-2015-02) and performed in accor-
dance with the Declaration of Helsinki and good clinical
practice guidelines. All patients provided written informed
consent and then received screening.
Randomization and masking
Using a computer-generated random number sequence,
the patients were randomly and evenly divided into groups
receiving sitagliptin 100 mg per day+ metformin+ insulin
glargine or voglibose 0.2 mg three times daily+metformin+
insulin glargine. The random numbers were stored in a closed
opaque envelope. The researchers and patients were aware of
the grouping and the drug interventions, but the investigators
in charge of data collection and analysis were masked to the
grouping and drug interventions.
Procedures
All patients received diabetes health education, diabetes diets
were provided by the nutrition department, and the patients
were instructed to comply with a routine exercise plan.
Patients in the sitagliptin group took sitagliptin (100 mg,
MSD, Hangzhou) 15 minutes before breakfast; patients in the
voglibose group took voglibose (0.2 mg, Takeda, Japan) three
times daily with meals. Metformin hydrochloride (0.5 g,
SASS, Shanghai) was also orally administered three times
daily with meals.
Subcutaneous injection of insulin glargine (Sanofi, France)
was administered prior to bedtime. Insulin glargine was
used at a dosage of 0.2 U  kg-1 d-1 initially. The amount of
insulin glargine was adjusted based on the results of a finger-
prick test. For patients who had fasting blood glucose (FBG)
X7 mmol/L for two consecutive days, insulin glargine was
increased by 2 U. For patients who had FBGo5 mmol/L or
showed hypoglycemia without obvious cause, the insulin
glargine dose was decreased by 2 U, as described previously
(14). Administration of insulin glargine was discontinued
when the dose was p10 U/d.
Every two weeks, telephone follow-up was conducted
to record the current amount of insulin intake, fasting and
postprandial blood glucose levels, hypoglycemic events
and fingertip blood glucose levels at that time. At baseline
and three months, the HbA1c level was examined, a 75-g oral
glucose tolerance test was conducted, and FPG, two-hour
postprandial plasma glucose (2-h PPG), fasting C peptide
(FCP) and 2-h C peptide (CP) were measured. In addition,
body weight was measured.
C peptide test: After fasting overnight, patients consumed
a mixture of 150 mL of warm water and 150 mL of 50%
glucose solution over a five-minute period. Venous blood
was drawn before and two hours after consumption of the
mixture. Serum FCP and 2-h CP levels were examined by
electrochemiluminescence. Morning FBG and 2-h PBG levels
after three meals were monitored using a finger-prick test
(ACCU-CHEK Performa, Roche, Germany) according to the
instructions (15). FPG, liver function, kidney function, and
blood lipids were measured by an automatic biochemical
analyzer (HITACHI 7600-210, Japan), and HbA1c was deter-
mined using HPLC (VARIANT-II, Bio-Rad, CA, USA). Hom-
eostatic model assessment of insulin resistance (HOMA-IR)
and b function (HOMA-b) were calculated according to well-
established methods (16).
Symptomatic hypoglycemia was defined as the occurrence
of dizziness, palpitations and other symptoms of sympa-
thetic nerve stimulation; biochemical hypoglycemia was
defined as a finger-prick blood glucose o4.4 mmol/L.
Outcomes
The change in HbA1c from baseline to week 12 was the
primary endpoint. The changes in FPG, 2-h PPG, HOMA-IR,
HOMA-b, and body weight at week 12 compared with
baseline, and duration and dosage of insulin application
were the secondary endpoints.
Statistical methods
The standard deviation was assumed to be 0.6%, as
described previously (9). If the difference in HbA1c between
the sitagliptin group and voglibose group was 0.5%, 33
patients were required in each group (66 patients in total) to
reach 90% power, permitting a 10% dropout rate; thus, a total
of 70 patients were included in the randomization.
The analysis of outcomes was conducted in accordance
with the principle of intention to treat.
Data that accorded with a normal distribution are expres-
sed as the mean ± standard deviation (x±s), intergroup
differences were compared by an independent samples t-test,
and intragroup differences were compared by a paired
sample t-test. All p-values were two-sided, and po0.05
indicates a statistically significant difference.
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From March 2015 to February 2016, 83 patients were
screened, and 70 were enrolled and randomized into two
groups. Six patients did not complete the 12-week follow-
up (Figure 1). No statistically significant differences in
initial characteristics were seen between the two groups
(Table 1).
Primary endpoint
At week 12, the initial changes in HbA1c were -6.00% in
the sitagliptin group and -3.58% in the voglibose group. The
difference between the groups was -2.42% (95% CI -1.91 to
-2.93, p=0.02) (Figure 2).
Secondary endpoints
After treatment, the decrease in FPG in the sitagliptin
group (-8.71±2.99 mmol/L) was significantly greater than
that in the voglibose group (-5.76±4.04 mmol/L), the
difference was -2.95 mmol/L (p=0.04), although the decrease
in 2-h PPG between the groups was not significantly
different (p=0.16) (Figure 3).
After treatment, the increase in HOMA-b in the sitagliptin
group (71.39±55.53) was significantly greater than that in
the voglibose group (27.48±25.14), with a difference of 43.91
(p=0.01). The decrease in HOMA-IR between the groups was
not significantly different (p=0.75) (Figure 4).
After 12 weeks, weight loss in the sitagliptin group (-3.77±
1.88 kg) was significantly greater than that in the voglibose
group (-1.54±1.05 kg), with a difference of -2.23 kg (p=0.01)
(Figure 5).
The duration of insulin glargine use in the sitagliptin
group (32±15 d) was significantly shorter than that in
the voglibose group (50±27 d), with a difference of -18 d
(p=0.04). The amount of insulin glargine administered was
not significantly different between the groups (sitagliptin
group 0.28±0.08 U  kg-1 d-1 vs. voglibose group 0.31±0.05
U  kg-1 d-1) (p=0.55).
Table 1 - Baseline characteristics of the S Group and V Group
(x±S).
S Group (n=35) V Group (n=35)
Sex (male/female) 20/14 18/16
Age (years) 41.2±10.0 43.1±12.0
Weight (kg) 76.15±13.57 76.72±9.36
WC (cm) 92.99±11.38 94.19±8.29
BMI (kg/m2) 26.23±3.45 26.86±2.57
SBP (mmHg) 130.26±8.35 131.33±12.61
DBP (mmHg) 82.75±5.50 82.26±8.47
FPG (mmol/L) 14.99±2.73 14.50±3.11
HbA1c (%) 11.9±1.5 10.6±1.1
TC (mmol/L) 5.54±1.36 5.16±1.04
TG (mmol/L) 2.17±1.54 1.73±0.88
HDL-C (mmol/L) 1.72±1.02 1.34±0.26
LDL-C (mmol/L) 3.32±0.98 3.26±0.74
S Group: Sitagliptin, V Group: Voglibose. WC: waist circumference,
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood
pressure, FPG: fasting plasma glucose, HbA1c: glycated hemoglobin A1c,
TC: total cholesterol, TG: triglyceride, HDL-C: high-density lipoprotein
cholesterol, LDL-C: low-density lipoprotein cholesterol.
Figure 1 - Enrollment.
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Safety endpoint
One patient in the sitagliptin group (2.9%) and three
patients in the voglibose group (8.6%) exhibited sympto-
matic hypoglycemia. No incidents of biochemical hypogly-
cemia or nocturnal hypoglycemia occurred in patients in
either group.
’ DISCUSSION
For newly diagnosed T2DM patients with high blood
glucose levels, intensive insulin therapy can quickly relieve
high glucose toxicity and improve islet cell function. In this
study, sitagliptin and voglibose added to insulin glargine
combined with metformin were compared in a 12-week
treatment regimen of a group of T2DM patients with high
blood glucose levels. The results showed that the decreases
in HbA1c and FPG in the sitagliptin group were significantly
higher than those in the voglibose group, and the decrease in
2-h PPG between the groups did not differ. This result might
have occurred because DPP-4 inhibitors reduce the degrada-
tion of glucagon-like peptides in the body, thereby increasing
glucose-dependent insulin secretion, inhibiting glucagon
secretion, and ultimately lowering fasting and postprandial
blood glucose levels (17). Alpha glucosidase inhibitors (AGIs)
reduce postprandial blood glucose primarily by reducing
intestinal carbohydrate absorption. Therefore, sitagliptin is
superior to voglibose for lowering fasting blood glucose levels
when either is combined with insulin and metformin.
Figure 2 - Comparison of HbA1c decline in the Sitagliptin and
Voglibose groups after treatment.
Figure 3 - Comparison of FPG and 2-h PPG decline in the Sitag-
liptin and Voglibose groups after treatment.
Figure 4 - Comparison of HOMA-b and HOMA-IR change from
baseline between the Sitagliptin and Voglibose groups after
treatment.
Figure 5 - Comparison of weight change between the Sitagliptin
and Voglibose groups after treatment.
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Since sitagliptin was superior to voglibose for lowering
fasting blood glucose levels, even though no significantly
different effects were seen on postprandial blood glucose
levels between the groups, sitagliptin was also more effective
than voglibose in reducing HbA1c. A similar conclusion was
reported in a previous study. Compared with AGIs, the effi-
cacy of sitagliptin in patients with poorly controlled T2DM
compared with that of stable glimepiride alone (mean HbA1c
7.7%) was assessed after 12 weeks. Notably, HbA1c was
reduced by -0.44% in the sitagliptin group (po 0.001) (18).
A meta-analysis confirmed that changes in HbA1c (weighted
mean deviation -0.30%; 95% CI -0.47 to -0.13%, po0.001) and
FPG levels (weighted mean deviation -0.50 mmol/L; 95% CI
-0.89 to -0.11 mmol/L, p=0.01) were significantly greater in
the DPP-4 inhibitor treatment group compared with that in
the AGI group (19).
The present study found that HOMA-b in the sitagliptin
group increased significantly after 12 weeks, suggesting a
significant improvement in islet function. In a double-blind,
crossover clinical trial, Tremblay et al. (20) found that T2DM
patients receiving sitagliptin therapy displayed significantly
improved islet function compared with patients receiving a
placebo. In the present study, the voglibose treatment group
also showed improved islet cell function and reduced insulin
resistance, consistent with the results reported by Do et al.
(21). The increase in HOMA-b in the sitagliptin group was
significantly greater than that in the voglibose group. This
finding suggests that sitagliptin more effectively protected
and improved islet cell function, possibly because DPP-4
inhibitors inhibit the degradation of incretin, which has an
indirect role in the inhibition of pancreatic b-cell apoptosis,
and promote the proliferation of b cells (22). Voglibose relieves
only high glucose toxicity to pancreatic b cells; therefore,
compared with the voglibose group, the sitagliptin group
showed better islet b cell protection.
In patients with newly diagnosed T2DM, glucotoxicity
and lipotoxicity could be effectively reduced by early insulin
therapy to alleviate insulin resistance and protect islet func-
tion (23). After short-term insulin therapy, patients with
highly elevated blood glucose levels can gradually reduce or
discontinue insulin treatment. In the present study, when the
insulin glargine dose was reduced to less than 10 U/d and
blood glucose was still well controlled, administration of
insulin glargine was discontinued. The duration of insulin
glargine use in the sitagliptin group (mean 32 d) was signif-
icantly shorter than that in the voglibose group (mean 50 d).
This result might be due to a better effect of sitagliptin on
lowering blood glucose and improving islet function; there-
fore, less insulin glargine was required to control blood
glucose. The fact that there was no difference between the
two groups in the average insulin dose per day per kilogram
of body weight indicates that the shorter period of insulin
use required in the sitagliptin group compared with that in
the voglibose group was not due to the insulin dose.
Weight loss can improve insulin sensitivity; therefore,
weight loss is essential for obese T2DM patients. The present
study showed significant weight loss in both groups after
treatment. Compared with placebo, DPP-4 inhibitors (24)
and AGIs (25) can reduce body weight, consistent with the
conclusions of our study. In addition, the sitagliptin group
displayed significantly more weight loss than the voglibose
group. A prospective, randomized, multicenter study trea-
ted T2DM patients with sitagliptin (50 mg/d) or voglibose
(0.6 mg/d) for 24 weeks, and weight loss with sitagliptin
treatment was significantly higher than that with voglibose
treatment (-1.3±3.2 kg vs. 0.4±2.8 kg) (26), consistent with
the results of the present study.
Hypoglycemia increases cardiovascular risk and is a
barrier to blood glucose control in patients with diabetes.
Our study showed that the sitagliptin group had one occur-
rence and that the voglibose group had three occurrences of
symptomatic hypoglycemia. No incidents of biochemical
hypoglycemia or nocturnal hypoglycemia occurred in either
group. Both treatments therefore resulted in a low incidence
of hypoglycemia and showed excellent safety. In our pre-
vious study, we compared the incidence of hypoglycemia in
newly diagnosed T2DM patients receiving combination
treatment with continuous subcutaneous insulin injection
and DPP-4 inhibitors or AGIs; two weeks of dynamic blood
glucose monitoring showed that both therapies have excel-
lent safety (12).
The limitations of our study are that the number of
included patients was relatively small and the follow-up
time was relatively short. The results therefore require veri-
fication in large-scale, multicenter clinical trials with more
patients and longer follow-up times.
In conclusion, compared with voglibose, sitagliptin added
to combined insulin and metformin therapy can achieve a
significantly better effect on lowering HbA1c and FPG and
shows excellent safety for newly diagnosed T2DM patients
with highly elevated blood glucose.
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